linjc16/ctgov huggingface dataset:
Efficacy of Artificial Intelligence-assisted Colonic Polyp Detection System

Study Overview
=================
Brief Summary
-----------------
This is a randomized controlled multicenter clinical trial of computer-aided detection (CADe) system for the adjuvant diagnosis of intestinal polyps/adenomas ever conducted in a Chinese population. In addition, this study will evaluate the effect of CADe system on adenoma detection of endoscopists under fatigue.

Official Title
-----------------
Research on the Auxiliary Diagnosis and Treatment System of Digestive Endoscopy Based on Artificial Intelligence: An Efficacy Study of Artificial Intelligence-assisted Colonic Polyp Detection System

Conditions
-----------------
Adenoma Colon

Intervention / Treatment
-----------------
* Device: AI-assisted colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Patients who need to undergo colonoscopy. - Exclusion Criteria:Patients with CRC, inflammatory bowel disease, previous colonic resection, and antithrombotic therapy precluding polyp resection were excluded. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AI-assisted group<br>Subjects in this group undergo AI-assisted colonoscopy. The AI-assisted system not only has the function of automatic polyp detection, but also has the function of colonoscopy quality control. | Device: AI-assisted colonoscopy<br>* AI can not only detect suspicious lesions timely, and label them in the field of view of the colonoscopy, but also monitor withdrawal speed and calculate the clean withdrawal time automatically.<br>|
| No Intervention: control group<br>Subjects in this group undergo routine colonoscopy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adenoma detection rate | The proportion of patients with at least one histologically proven adenoma or carcinoma | up to 2months | 
| withdrawal time compliance rate | The proportion of patients with clean withdrawal time >6min. | up to 2months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| polyp detection rate | The proportion of patients with at least one polyp. | up to 2 months | 
| adenoma per colonoscopy | The number of adenomas detected per colonoscopy | up to 2 months | 
| polyp per colonoscopy | The number of polys detected per colonoscopy | up to 2 months |
Imaging of Vitreous Opacities in Human Eyes

Study Overview
=================
Brief Summary
-----------------
Vitreous opacities (VOs), commonly known as floaters, are dark spots that appear in, and may float across your vision. Presently, there is a lack of available data in the literature regarding VOs. This study aims to obtain imaging data of VOs in the population to build an imaging database of VOs to learn more about them.

Official Title
-----------------
Evaluation of a Non-Invasive Imaging Device for the Acquisition of Imaging Data of Vitreous Opacities in Human Eyes

Conditions
-----------------
Floaters, Vitreous Opacities

Intervention / Treatment
-----------------
* Device: SVO-ID


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female Aged 18 years or older SVO-related symptoms in vision Clear ocular media, to allow a clear view of the vitreous for the SVO-ID Exclusion Criteria: Individuals under 18 years of age Presence of active bleeding in the retina Cataract Grade 3 and above Opacification of lens or cornea, lens, or vitreous (that would preclude clear imaging by the SVO-ID) Principal Investigator's determination that the subject is not suitable

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Imaging using the SVO-ID<br>Patients will have their eyes imaged with the SVO-ID as part of a study visit. | Device: SVO-ID<br>* Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful capture of SLO and OCT imaging data of SVOs for algorithm development | Successful collection of SLO and OCT imaging data | Through study completion, an average of 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of patient-reported symptoms | Patient feedback regarding symptoms related to SVOs being imaged | Through study completion, an average of 6 months |
Opportunistic Fragility Fracture Risk Estimates From Radiographs

Study Overview
=================
Brief Summary
-----------------
The proposed study will predict a patients' risk of having osteoporosis by using a combination of the IBEX BH (Bone Health) software outputs and other clinical risk factors such as age, gender, medical history and lifestyle. A comparison will be made between the IBEX BH prediction and the one calculated in current clinical practice using a tool called FRAX (Fracture Risk Assessment Tool) which combines clinical risk factors with results from a Dual Energy X-ray Absorptiometry (DXA) assessment. The study involves conducting these assessments on several new anatomies including Knee, Ankle and Pelvis, to extend the market reach and clinical utility of IBEX BH. The expected outcome of the study is that the IBEX BH will offer better decision support to clinicians in terms of referral on for a DXA scan or osteoporosis investigations than available today.

Official Title
-----------------
Opportunistic Fragility Fracture Risk Estimates From Radiographs

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Device: IbexBH Software


Participation Criteria
=================
Eligibility Criteria
-----------------
For the collection of test data in the study. Inclusion Criteria: Male or female 50 years of age or over Exclusion Criteria: Women who are pregnant or are breastfeeding. Participants who have sustained fractures in both hips. Unwilling or unable to provide informed consent. For the collection of healthy-normal data in the study. Inclusion Criteria: Male or female 20-30 years of age Exclusion Criteria: Women who are pregnant or are breastfeeding. Participants who have sustained fractures in both hips. Unwilling or unable to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: IbexBH Software|A software application applied to radiographs|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| T-scores as calculated by IbexBH and DXA |  | 2 hours on 1 visit only | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimated 10-year risk of major osteoporotic fracture as outputted by FRAX (with and without DXA aBMD (Areal Bone Mineral Density) and IbexBH) |  | 2 hours on same visit as above |
Effect of Thyroid Disorders in Liver Diseases

Study Overview
=================
Brief Summary
-----------------
Aims of the Research To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD). To detect hepatic risk in subclinical and clinical hypothyroidism . To detect early liver disorders in thyroid disorders using fibroscan .

Detailed Description
-----------------
Non alcoholic fatty liver disease (NAFLD) has been a health problem of growing significance all over the world; its prevalence is increasing in both developed and developing countries ,the overall prevalence of NAFLD worldwide was estimated to be 32.4%.prevalence increased significantly over time. considering the increasing incidence of NALAD/NASH, especially in developed and developing countries, it is anticipated that cirrhosis due to these conditions may exceed other causes of cirrhosis in a near future.. Thyroid gland is involved in energy homeostasis, lipid and carbohydrate metabolism, regulation of body weight and adipogenesis. In a clinical setting, subclinical hypothyroidism has been associated with metabolic syndrome, cardiovascular mortality and disturbance of lipid metabolism. The prevalence of hypothyroidism was reported to 16.8% among patients with NAFLD/NASH. In recent years, growing body of evidence has led to speculation on the association between NAFLD/NASH and thyroid dysfunction. Therefore, understanding the pathophysiology, risk factors and new treatment options of NAFLD/NASH should be among the priorities in the field of hepatology

Official Title
-----------------
Effect of Thyroid Disorders in Metabolic Fatty Liver Changes

Conditions
-----------------
Fatty Liver Disease

Intervention / Treatment
-----------------
* Device: Fibroscan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The study will include thyroid patients over one year duration ( age above 18 years old Exclusion Criteria: History of liver failure or patient known to have congenital liver disease. Medications associated with weight gain . Patients who have diabetes mellitus. patients who already have liver disease eg; chronic viral hepatitis, liver cirrhosis. Patients on antistatin.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Fibroscan|Scan the liver for metabolic fatty changes|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detect correlation between hyperthyroid diseases and NASH . | Test the patients of thyroid disorders for metabolic fatty liver changes | Baseline |
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection

Study Overview
=================
Brief Summary
-----------------
To study the current status of cardiotoxicity of arsenious acid by analyzing the literature, monitoring data, and real-world applications, and to discuss risk factors and preventive and control measures.

Detailed Description
-----------------
Through the project study, the risk rate of cardiotoxicity caused by arsenious acid will be verified and evaluated, and a typical case analysis will be conducted to assess the risk and benefit ratio of clinical use of arsenious acid injection and to formulate preventive measures, so as to guide the holder of the marketing authorization to carry out in-depth safety studies and to ensure the public's safe use of the drug.

Official Title
-----------------
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection

Conditions
-----------------
Adverse Reaction, Cardiotoxicity, Evaluation Study

Intervention / Treatment
-----------------
* Drug: Sodium arsenite chloride injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the period of consultation (for inpatients, according to the time of admission) is from January 1, 2012 to December 31, 2022 the patient used arsenite sodium chloride injection Exclusion Criteria: Patients with incomplete clinical information
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| arrhythmia | Electrocardiogram shows arrhythmia with marked QT prolongation | through study completion, an average of 1 year | 
| adverse reaction | All cardiac-related adverse events in the course of the disease regimen | through study completion, an average of 1 year | 
| troponin | Troponin values | through study completion, an average of 1 year | 
| Echocardiogram LVEF | Echocardiogram LVEF values | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
arsenious acid, arsenic trioxide, cardiotoxicity
HNC: Human Neural Circuits Electrophysiology During Cognition

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Detailed Description
-----------------
The goal of this proposed research is to record the effects of ketamine on brain activity to understand the changes that occur during antidepressant therapy and the side effect of dissociation. This research is designed to probe altered cognitive states associated with dissociation, depression, and other neuropsychiatric conditions.

Official Title
-----------------
HNC: Human Neural Circuits Electrophysiology During Cognition

Conditions
-----------------
Psychiatric Disorder

Intervention / Treatment
-----------------
* Drug: Ketamine Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient in clinical neuro inpatient units at Stanford Medical Center Age >18 years old Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex) Exclusion Criteria: Lifetime psychotic disorder Pregnant or nursing females Prior adverse ketamine response Use of ketamine in past 7 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketamine<br>Study participants will receive 0.5mg/kg of ketamine - one single infusion | Drug: Ketamine Hydrochloride<br>* Ketamine is an FDA-approved dissociative anesthetic.<br>* Other names: Ketalar;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale) | The CADSS is an instrument for the measurement of dissociative symptoms. The CADSS comprises 23 subjective items and participant's responses are coded on a 5-point scale (0 = Not at all; 4 = Extreme). The higher the number on the CADSS, the more severe the symptoms. | up to 1 week |
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

Study Overview
=================
Brief Summary
-----------------
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia.

Detailed Description
-----------------
The study is being conducted to validate the feasibility of remote assessment of Tardive Dyskinesia. Participants will all be taking an antipsychotic medication and half will have a diagnosis of Tardive Dyskinesia and half will not. Participant responses to interview questions and elements of the Abnormal Involuntary Movement Scale will be collected on video. The videos will be rated by trained observers. Machine learning methods will be used to develop an algorithm to detect abnormal movements in individuals with a known Tardive Dyskinesia diagnosis. The trained rater results will be compared to the algorithm to determine the accuracy of the algorithm.

Official Title
-----------------
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

Conditions
-----------------
Tardive Dyskinesia

Intervention / Treatment
-----------------
* Other: TDtect


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For the non-TD group: Prescribed and taking an antipsychotic medication for 90-days or longer. Tardive Dyskinesia symptoms if present are not from Parkinsons, Tourette's syndrome, Huntington disease. Signed an informed consent. Speaks English fluently. Exclusion Criteria: Suffered a moderate or severe head injury in the last year; History of a learning disorder or developmental disability that would inhibit a patient from completing the TD protocol. Severe visual impairment that is cannot be corrected by glasses or contacts.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Open-label, observational study with two groups taking antipsychotic with or without Tardive Dyskinesia
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Taking antipsychotic medication with Tardive Dyskinesia<br> | Other: TDtect<br>* Collecting video data on abnormal movement<br>|
| Other: Taking antipsychotic medication without Tardive Dyskinesia<br> | Other: TDtect<br>* Collecting video data on abnormal movement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AIMS Score | Abnormal Involuntary Scale Score | Baseline |
A Study of the Effect of Food on LY3537982 in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 after meals and on an empty stomach. The study will also evaluate the safety and tolerability of LY3537982. Participants will stay in the research center during the study, which will last about one week, not including screening.

Official Title
-----------------
A Phase 1 Study to Evaluate the Effect of Food on the LY3537982 Pharmacokinetics in Health Adult Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: LY3537982


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive Exclusion Criteria: Females who are lactating or of childbearing potential Clinically significant history of any drug sensitivity, drug allergy, or food allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LY3537982 (High-Fat Meal)<br>LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard high-fat meal) in the other study period. | Drug: LY3537982<br>* Administered orally.<br>|
| Experimental: LY3537982 (Low-Fat Meal)<br>LY3537982 administered orally under fasting conditions in one study period and under fed conditions (i.e., a standard low-fat meal) in the other study period. | Drug: LY3537982<br>* Administered orally.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC[0-inf]) | PK: AUC(0-inf) | Day 1 and Day 4 of each study period | 
| PK: Maximum Observed Concentration (Cmax) of LY3537982 | PK: Cmax of LY3537982 | Day 1 and Day 4 of each study period |